NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) YMAB securities.

If you have purchased Y-mAbs securities and would like to discuss our investigation, please contact us via email jcampisi@kaplanfox.com or by calling (212) 687-1980.

On October 31, 2022, Marketwatch published an article stating, “Shares of Y-mAbs Therapeutics Inc. YMAB, +0.90% Plunged 42.5% Monday in premarket trading after several banks downgraded the company’s shares and a Food and Drug Administration advisory committee voted against approving the company’s experimental treatment for neuroblastoma patients.

The article goes on to say that the “committee voted 16-0 on Friday that there is insufficient evidence to say omburtamab improves overall survival The news flow bodes well for investor confidence or for follow-up indicators, Wedbush also downgraded the stock to neutral from outperform. Y-mAbs stock is down 44.9% this year, while the broader S&P 500 SPX, +2.46% down 18.5%.”

This press release may be considered an attorney’s advertisement in some jurisdictions under applicable laws and ethics rules.

WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focused on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of securities disputes experience, Kaplan Fox provides the professional experience and track record that clients demand. By prosecuting cases at the federal and state levels, Kaplan Fox has successfully shaped the law by winning many important decisions on behalf of our clients. For more information on Kaplan Fox & Kilsheimer LLP, please visit…